Key Highlights

  • Argenica Therapeutics (ASX: AGN) traded at A$0.20, up 17.65% or A$0.03, at 2:02pm on 17 August 2026.
  • The company is advancing preparations for a late-stage clinical trial of ARG-007, now named xaranetide, in moderate to severe acute ischaemic stroke.
  • Three FDA-requested safety assays covering hERG, TNK and genotoxicity have been completed, with the company reporting favourable safety profiles.
  • Argenica held A$6.35 million in cash reserves at 30 June 2026 and is preparing a response to the FDA clinical hold.

Argenica Therapeutics Limited (ASX:AGN) was trading at A$0.20, up 17.65%, or A$0.03, at 2:02pm on 17 August 2026. The move follows the company’s 24 July quarterly activities and Cash Flow update, which outlined progress toward a late-stage clinical trial for ARG-007, now known by the International Nonproprietary Name xaranetide, in moderate to severe acute ischaemic stroke.

Late-Stage Stroke Trial Preparation Advances

During the June quarter, Argenica focused on preparations for a late-stage trial targeting acute ischaemic stroke patients. The company convened a global Stroke Clinical Advisory Committee comprising international experts to review and optimise the proposed clinical trial design.

The planned study is intended to use a precision-medicine strategy. According to the company, this approach is designed to support patient identification and trial enrolment while improving the prospects of generating a meaningful clinical result.

Argenica previously completed a Phase 2 clinical trial of ARG-007 in acute ischaemic stroke patients across Australian hospitals during 2025. The company said the study generated safety and functional efficacy data that are supporting development of the next-stage trial.

FDA Requirements and Safety Testing

A significant part of the quarter involved completing three assays requested by the US Food and Drug Administration. The hERG, TNK and genotoxicity assays were completed, with Argenica reporting clean and favourable safety profiles from the testing.

The company is now working toward finalising the protocol for the proposed late-stage trial. Once the protocol is completed, Argenica plans to submit a comprehensive response to the FDA clinical hold and seek approval of the Investigational New Drug application for ARG-007.

FDA clearance of the IND would represent a further regulatory step before a US clinical trial could commence. The current update does not establish that such approval has been granted.

Xaranetide Development Expands Beyond Stroke

The World Health Organisation has confirmed xaranetide as the International Nonproprietary Name for ARG-007. Argenica is also examining the drug candidate in other neurological conditions.

During the quarter, xaranetide demonstrated neuroprotective effects in a preclinical concussion study, adding to research across mild, moderate and severe traumatic brain injury models. The company said it is considering the next steps for development in this area.

The broader development program remains at different stages, with the acute ischaemic stroke program currently receiving the principal late-stage development focus.

Cash Position and Funding

Argenica reported A$6.35 million in cash reserves at 30 June 2026. The company said the balance provides funding to continue preparatory activities for its targeted late-stage acute ischaemic stroke trial.

The company has also secured non-dilutive funding during the development of the program. In June 2025, Argenica was awarded up to A$1.5 million through the Australian Government's Medical Research Future Fund Targeted Translation Research Accelerator program for Diabetes and Cardiovascular Disease.

Across its projects, the company said it has secured more than A$4 million in non-dilutive grant and philanthropic funding over the life of its research programs.

Conclusion

Argenica's latest quarterly update places its stroke drug candidate xaranetide at an important development stage, with preparations advancing for a proposed late-stage acute ischaemic stroke trial. Completion of the three FDA-requested assays removes one set of testing requirements identified by the regulator, while protocol finalisation and a response to the clinical hold remain ahead. The company entered the new quarter with A$6.35 million in cash reserves and continues to pursue non-dilutive funding alongside development activities. The next milestones are therefore centred on finalising the trial protocol, responding to the FDA and seeking IND approval for the US clinical program.